Tom Blackburn FBPharmacolS, FRSB (born 1949) is a British industrial pharmacologist.
Tom Blackburn | |
|---|---|
| Born | 1949 (age 74–75) |
| Nationality | United Kingdom |
| Alma mater | |
| Occupation | Industrial pharmacologist |
| Employers | |
Blackburn studied at both the University of Nottingham and Manchester University, and worked as a senior manager at ICI Pharmaceuticals, Beecham Pharmaceuticals SmithKline Beecham, Synaptic Pharmaceutical Corporation and Helicon Therapeutics.[1]
He is the author of over 100 scientific papers, reviews and book chapters and holds over 20 patents.[1] He is President Emeritus of the British Pharmacological Society and is a member of the American College of Neuropsychopharmacology.[1]
He was elected an Honorary Fellow of the British Pharmacological Society (Hon FBPharmacolS) in 2014 and is a Fellow of the Royal Society of Biology (FRSB).[2]
References
edit- ^ a b c Caroline Overy; Tilli Tansey, eds. (2013). Drugs Affecting 5-HT Systems. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-902238-87-9. Wikidata Q29581800.
- ^ "Dr Thomas Blackburn". British Pharmacological Society. Retrieved 3 August 2017.
External links
edit- Tom Blackburn on the History of Modern Biomedicine Research Group website
- Interview with Blackburn playlist on YouTube - conducted by Professor Tilli Tansey, for the History of Modern Biomedicine Research Group, 22 February 2016 (seven parts)
 | This article about a biologist from the United Kingdom is a stub. You can help Wikipedia by expanding it. |
 | This biographical article related to medicine is a stub. You can help Wikipedia by expanding it. |